FMN2

Across TCGA pan-cancer cohorts, FMN2 Mutation is linked to patient survival in 13 of 34 cancer types, making it a survival-associated FMN2 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher FMN2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FMN2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

DLBC, UCEC, and BRCA are the cancer types where FMN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	All	0.049	0.765	<.001	30	view →
UCEC	DFS	Median	All	0.975	0.821	.002	22	view →
BRCA	OS	Median	III,IV	0.191	0.833	<.001	19	view →
CHOL	DFS	Median	All	0.045	0.497	.029	12	view →
CESC	OS	Median	III,IV	0.156	0.657	.027	12	view →
STAD	DFS	Median	All	1.000	0.439	.023	12	view →
KIRC	OS	Median	All	0.167	0.655	.038	6	view →
BLCA	OS	Median	IV	0.785	0.314	.030	4	view →
SKCM	DFS	Median	II,III,IV	0.801	0.644	.009	4	view →
KIRP	OS	Median	II,III,IV	0.199	0.771	.030	3	view →
SARC	DFS	Median	All	0.179	0.594	.031	3	view →
ESCA	OS	Median	All	0.250	0.564	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

FMN2–DLBC (OS)

Open the DLBC breakdown →